Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSL889 in Sickle Cell Disease Vaso-Occlusive Crisis (Phase 2/3)
2024-513440-29-00Phase 3Completed
- Sponsor
- CSL Behring
- Start
- Apr 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in sickle cell disease (SCD) comparing CSL889 (human hemopexin) with Placebo (2 arms). Primary endpoints: Time to resolution of vaso-occlusive crisis, Number of participants with treatment-emergent adverse events and 3 more. Started Apr 2025; status: completed.
02
Drugs
hemopexin
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2024-513440-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513440-29-00.